Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial
Naslov
                                Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial            
                            Identifikator
                                /unibl/sci/idNaucniRad:24616            
                            Tip
                                Pronađite slične unoseAcademic Article            
                                                        
                            Datum
                                Pronađite slične unose2019-06            
                            Bibliografski citat
                                S. Cheol Shim, LJ. Božić, A. Berrocal Kasay, E. Chalouhi El-Khouri, F. Irazoque-Palazuelos, F. Fidencio Cons Molina, F. G Medina-Rodriguez, P. Miranda, P. Shesternya, J. Chavez-Corrales, P. Wiland, S. Jeka, O. Garmish, P. Hrycaj, N. Fomina, W. Park, C. Hee Suh, S. Joon Lee, S. Young Lee, Y. Ju Bae, D. Hyun Yoo, Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial, RHEUMATOLOGY, pp. 2193 - 2202, Jun, 2019            
                            Početna stranica
                                2193            
                            Krajnja stranica
                                2202            
                            Je dio
                                RHEUMATOLOGY            
                                                        
                                1462-0324            
                            Lista autora
Position: 7719 (155 views)
